Other

University of California

One Lambda, Inc.

Paul I Terasaki

Mepur H Ravindranath

Adam Idica

Chun-Tsan Deng

Dennis Aoki

Jimmy Loon

Ronald J Billing

Kiyoyasu Fukushima

Masaki Hirota

Nadim El-Awar

Takashi Iguro

Steven Hardiwidjaja

Akemi Wakisaka

Provided herein are compositions comprising anti-HLA-Ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunomodulatory or immunosuppressive activities. Methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.

Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use

Provided herein are compositions comprising purified antibodies and fragments thereof that are specifically immunoreactive to only human leukocyte antigen E (HLA-E) but not to other HLA Ia and HLA-Ib alleles. Also provided are methods of their making and diagnostic and therapeutic applications. The monospecific HLA-E antibodies are highly specific and can be used for diagnosing or localizing the presence of HLA-E on normal or diseased cells or tissues. The monospecific HLA-E antibodies can also be used for cancer therapies, likely through regulation of the CD94/NKG2a on Cytotoxic and/or Natural Killer T cells.

Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E

Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.

Compositions and methods for the detection of antibodies to native human leukocyte antigen

Hybrid cell line producing monoclonal antibodies reactive with human activated lymphocytes, monocytes and cancer cells directed against a growth factor of approximately 15,000 daltons. Diagnostic and therapeutic uses of the antibody and antigen in cancer, autoimmune disease and transplant rejection are discussed.

Monoclonal antibody specific for activated lymphocytes and monocytes

A composition of matter and method for using the composition of matter to isolate various cell elements from a heterogeneous cell suspension in a simple one step procedure. The composition is a monoclonal antibody mixture including complement and a non-toxic density gradient media. The composition provides a negative selection technique in which undesired subpopulation cells are lysed and separated from the desired cell subpopulation. The invention has particular application to isolation of white cell elements.

Method and composition for isolating white cell elements

Detection of sialylated Lewis.sup.x antigen in sera is employed as diagnostic of the presence of cancer. Conveniently, monoclonal antibodies are provided which are shown to be useful in the diagnosis of a neoplastic condition, with a wide variety of different tumors. The hybridoma CSLEX1 was deposited at the A.T.C.C. on June 20, 1984 and given Accession No. HB8580.

Sialylated Lewis.sup.x epitope, antibodies and diagnosis

A microdroplet test apparatus for use in HLA typing. The apparatus is an improvement upon the well known Terasaki tray which is in use for determining HLA antigens by measuring lymphocyte cytotoxicity. The apparatus includes a tray having a plurality of microtest wells wherein the sides of the microtest wells are designed to promote localization of lymphocytes or other cells being tested at the microtest well bottom. The apparatus further includes a cover having either rods or tubes which extend down into the test solution present in the microtest well to thereby control the amount of test solution which is present in the cylindrical optical view path through which the test solution is viewed by microscope for test result measurements. This allows control of the amount of test solution in the optical view path in order to reduce the amount of solution which must be looked through when cells are being counted or alternatively, increasing the amount of test solution present in the view path in order to maximize detection when a colored reaction product in the test solution is being measured.

Growing community of inventors

Los Angeles, CA, United States of America

Paul I Terasaki